DIASYST Inc.

<p>DIASYST is a comprehensive, EHR-integrateable solution built to revolutionize the management of common and costly diseases, including diabetes, hypertension, and hyperlipidemia. We engage patients to collect critical information in real time, analyze the data with proprietary algorithms, and provide time-appropriate pharmacological intervention recommendations for the healthcare team to make effective, individualized, and safe treatment decisions. By deploying DIASYST, providers will be able to achieve key clinical, operational, administrative, and financial goals, such as:</p> <ul> <li>Improved A1c and blood glucose levels of type 2 diabetics, reducing the incidence of both hyper- and hypoglycemia</li> <li>Reduced risks of developing diabetes complications, including heart attack, stroke, kidney failure, blindness, and foot amputations</li> <li>Reduced ED visits, hospital stays, and readmissions</li> <li>Reduced office visits and phone calls for optimal patient care, which will: <ul> <li>Increase patient access to care</li> <li>Increase provider productivity and capacity</li> <li>Improve patient satisfaction and retention</li> <li>Decrease costs of care</li> <li>Increase provider-patient engagement</li> </ul> </li> <li>Scaled specialist endocrinology-level care to primary care, mid-level providers, and pharmacists, who manage over 95% of all diabetics</li> <li>Increase value-based and fee-for-service-based reimbursements, through improvements in MIPS and ACI measures as well as increases in telehealth/remote monitoring collections</li> </ul>

<p>By helping providers monitor and control blood glucoses of their high-risk patients, DIASYST reduces the risks of developing diabetes complications, including heart attacks, strokes, kidney failure, blindness, and foot amputations, and helps reduce ED visits, hospital stays, and readmissions. DIASYST is very suitable for transitioning care from the hospital to the patient home, particularly for patients admitted initially due to severe hyperglycemia, hypoglycemia, or other diabetes-related factors.</p>

<p>&bull; Payers, shared-savings programs, and Medicare Advantage programs that will benefit from lowered costs due to improved diabetes management</p> <p>&bull; Large employers that will develop a more productive and healthier workforce while decreasing healthcare expenses</p> <p>&bull; Pharmacies that would benefit from increased patient engagement, medication adherence, and decreased DIR fees&nbsp;&nbsp;</p> <p>&bull; Diabetes drug and device manufacturers that will benefit from more, better, and safer use of their products</p> <p>&bull; Electronic health record companies with third-party app programs as channels into healthcare provider users</p>